''To date, #tixagevimab-cilgavimab cannot be considered a substitute for #vaccination but may be a useful supporting #therapy if the recommended dose for pre-exposure prophylaxis is doubled.''

Impaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19

#Breakthrough #SARS-CoV-2 #Infections in the PROVENT #Prevention Trial Were Not Associated with AZD7442 (#Tixagevimab/Cilgavimab) Resistant Variants https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad210/7191107?rss=1

#Genotypic and Predicted #Phenotypic #Analysis of #SARS-COV-2 #Omicron #Subvariants in Immunocompromised Patients with #COVID19 Following #Tixagevimab-Cilgavimab Prophylaxis https://www.sciencedirect.com/science/article/pii/S1386653223000057?dgcid=rss_sd_all

#Safety, Tolerability and Pharmacokinetics of Half-Life Extended #SARS-CoV-2 Neutralizing Monoclonal #Antibodies #AZD7442 (#Tixagevimab / #Cilgavimab) in Healthy Adults https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad014/6997870?rss=1

Brevetti e pillole amare: l’Ue continua a difendere Big Pharma, non solo sui vaccini https://altreconomia.it/brevetti-e-pillole-amare-lue-continua-a-difendere-big-pharma-non-solo-sui-vaccini/ #CorporateEuropeObservatory #immunosoppressore #Approfondimento #astrazeneca #monoclonali #Tixagevimab #Tocilizumab #Sotrovimab #anticorpi #covid-19 #pfizer #covid #Merck #Roche #GSK